U.S. Biotech Stock News

At the Barclays Financial Services Conference in September, MarketAxess CEO Chris Concannon and CFO Ilene Fiszel Bieler outlined the company’s evolving growth plan, emphasizing progress in non‑US credit revenue, stronger algorithmic and block trading activity, and plans to deepen integration with ICE Bonds while prioritizing organic growth and selective share repurchases. An interesting takeaway is management’s emphasis on emerging markets, where electronic bond trading remains minimal,...

In recent months, BioMarin Pharmaceutical reported very large year-over-year EPS growth in Q2 2025, highlighted the margin benefits of its 2024 restructuring, and raised guidance for revenue, income, and operating margins while pointing to limited competition for its orphan drug portfolio. Management now expects the full impact of these cost and efficiency measures to emerge in 2026, with promising late-stage trials potentially adding to an already focused rare-disease franchise. Next, we’ll...

To the annoyance of some shareholders, Elutia Inc. ( NASDAQ:ELUT ) shares are down a considerable 28% in the last...

Recent upward revisions to earnings estimates have pushed Fiverr International (FVRR) into the spotlight, as a stronger earnings outlook and favorable ranking are drawing fresh attention from investors watching the freelancing platform. See our latest analysis for Fiverr International. Those upgraded earnings expectations have helped the stock stabilize recently, with a 30 day share price return of 4.8% following a weak year to date share price return of negative 32.8%. This signals improving...

In the third quarter, New York-based Commodore Capital increased its stake in Relay Therapeutics by nearly 3.7 million shares, bringing its holdings to 17 million shares valued at about US$88.70 million, as the company cut expenses and reduced its quarterly net loss while maintaining a cash runway into 2029. Renewed institutional interest appears closely tied to Relay’s advancing clinical programs, particularly RLY-2608 in breast cancer and vascular malformations, which investors may see as...

In late November 2025, QuidelOrtho drew heightened attention after director Joseph D Jr. Wilkins bought 370 shares and CEO Brian J. Blaser purchased 23,500 shares, signaling leadership’s willingness to commit personal capital to the diagnostics company. These insider purchases have become a focal point for investors, who often treat such buying as a real-time indicator of management’s conviction in the company’s prospects. We’ll now examine how this insider buying wave could influence...

If you are wondering whether Constellation Energy at around $359 a share is still worth chasing after a huge multi year run, you are not alone. This is exactly the question we will unpack. The stock has dipped slightly in the last week and month, down about 1.2% over 7 days and 0.9% over 30 days, but it is still up 48.3% year to date and 42.7% over the last year, with a 311.0% gain over 3 years. Those kinds of returns have been associated with rising optimism around US power markets and the...

Smithfield Foods (SFD) has been quietly grinding higher this year, and that steady climb has plenty to do with its improving fundamentals, from modest revenue growth to faster expanding profits. See our latest analysis for Smithfield Foods. At a last close of $21.93, Smithfield’s year to date share price return of 11.04% signals improving sentiment as investors gradually price in its steady earnings momentum rather than chasing short term swings. If this kind of steady compounding appeals to...

The Digital Turbine, Inc. ( NASDAQ:APPS ) share price has softened a substantial 31% over the previous 30 days, handing...

TJX Companies (TJX) just posted another quarter of sales growth while laying out multi billion dollar plans to upgrade stores, distribution, and e commerce. This combination helps explain the stock’s steady climb. See our latest analysis for TJX Companies. That growth story seems to be resonating with investors, with the share price now around $153.28 after a roughly 26.5% year to date share price return and a powerful three year total shareholder return of about 105 percent, helped by steady...

Many EverQuote, Inc. ( NASDAQ:EVER ) insiders ditched their stock over the past year, which may be of interest to the...

Lennar (LEN) has been grinding through a mixed stretch, with the stock slipping over the past 3 months even as revenue edges higher and long term returns remain a focal point for patient investors. See our latest analysis for Lennar. At around $123.91, Lennar’s recent share price pullback, including a weaker 1 week share price return, contrasts with its solid multi year total shareholder returns. This suggests sentiment has cooled even as the long term housing story remains intact. If...

In early December 2025, Business Alliance Financial Services (BAFS) announced it had integrated its BLAST commercial lending platform with Fiserv’s Portico account processing system, giving credit unions using Portico more options to digitize and streamline their commercial loan lifecycles. This integration, alongside Fiserv’s appointment of veteran technology-sector analyst Walter Pritchard as Head of Investor Relations, underscores the company’s emphasis on expanding higher-value software...

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

Investors who take an interest in Advanced Flower Capital Inc. ( NASDAQ:AFCG ) should definitely note that the...

MGP Ingredients, Inc.'s ( NASDAQ:MGPI ) price-to-sales (or "P/S") ratio of 0.9x might make it look like a buy right now...

Key Insights Significant control over CSP by individual investors implies that the general public has more power to...

Key Insights Significant insider control over iHuman implies vested interests in company growth Yufeng Chi owns 56% of...

With a median price-to-earnings (or "P/E") ratio of close to 19x in the United States, you could be forgiven for...

Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Typically, we'll want...

Capricor Therapeutics (CAPR) has quietly rewarded patient investors, with the stock climbing sharply over the past year as expectations build around its late stage Duchenne muscular dystrophy program and broader exosome pipeline. See our latest analysis for Capricor Therapeutics. The recent surge, including a powerful 7 day share price return and strong gains over the past quarter, suggests momentum is firmly building as investors reprice Capricor’s late stage pipeline and long term...

In recent days, Kontoor Brands reported quarterly earnings per share that surpassed analyst estimates and announced a new quarterly dividend, prompting analysts to reiterate a consensus "Moderate Buy" rating. This combination of an earnings beat, income-focused capital return, and broad-based analyst support has reinforced confidence in Kontoor’s underlying business momentum and execution. We’ll now examine how this earnings surprise and dividend declaration could influence Kontoor Brands’...

In late 2025, NetApp introduced Amazon S3 Access Points for Amazon FSx for NetApp ONTAP, allowing AWS AI and analytics services to access NetApp-managed data in the cloud and on-premises without moving it, while preserving full file protocol access and ONTAP’s cyber‑resilience features. This deeper integration with AWS positions NetApp’s storage platform more firmly at the center of AI and analytics workflows, potentially increasing the relevance of its hybrid cloud and subscription...

Recently, Elastic announced a new integration that brings observability for AI agents and applications running on Amazon Bedrock AgentCore directly into the Elasticsearch platform, alongside a US$500.00 million share repurchase program and stronger fiscal second quarter 2026 results. The company is also deepening its AI focus through an investment in investigations software firm Siren and gaining AWS Agentic AI Specialization, underscoring its emphasis on production-grade autonomous AI...